Combination of IVF protocol antagonists with other adjuvant therapies
In vitro infant protocol antagonist is an important treatment method in assisted reproductive technology. It can regulate ovarian function and control follicular development and ovulation time by intervening hormone levels. However, the therapeutic effect of only relying on antagonists may not be good, so the combination with other adjuvant therapies has become a common choice. This article will elaborate on the combination of IVF protocol antagonists and other adjuvant therapies from four aspects: ovulation induction therapy, ovarian adjuvant therapy, embryo transfer pre-treatment and early pregnancy monitoring.
Ovulation induction
In vitro infant protocol antagonists are often used in combination with follicle stimulating hormone (FSH) to improve ovarian responsiveness and polycystic follicle development. Antagonists can inhibit the secretion of luteinizing hormone, thus reducing the inhibitory effect of progesterone on luteinization and maturation, and increasing the number and quality of polycystic follicles. In addition, antagonists can also reduce early luteal failure, improve embryo quality, and thus increase the success rate of IVF.
The combination treatment of antagonist and follicle stimulating hormone needs to pay attention to adjusting the dosage and time of medication. The individualized treatment plan can be adjusted according to the patient's age, ovarian reserve function and ovarian responsiveness to achieve the best treatment effect.
Ovarian adjuvant therapy
Ovarian adjuvant therapy is an important part of IVF program. It can improve the rate of oocyte acquisition and fertilization by increasing the number of follicles and improving the quality of follicles. Antagonists are often used as the first step of adjuvant ovarian therapy to inhibit early ovulation and luteinizing hormone secretion.
In adjuvant ovarian therapy, antagonists can be used in combination with follicle stimulating hormone or other adjuvant therapies. For example, combined use with growth hormone and luteinizing hormone can improve ovarian responsiveness, improve follicular quality, and increase the success rate of pregnancy. In addition, antagonists can also be used in combination with ovarian stimulants to increase the number and quality of follicles.
Pretreatment of embryo transfer
The pretreatment of embryo transfer is one of the key links in the IVF program, which can select the best embryo and improve the implantation rate and pregnancy success rate. Antagonists are widely used in pretreatment of embryo transfer.
Antagonists can reduce the maturation and senescence of endometrium by inhibiting the secretion of luteinizing hormone, providing favorable conditions for embryo implantation. In addition, antagonists can also improve the uterine environment and increase the chances of embryo implantation by adjusting the hormone level of endometrium.
Early pregnancy monitoring
Early pregnancy monitoring is one of the important links in the success rate of IVF. It can detect and deal with pregnancy complications as early as possible to ensure the safety of mothers and infants. Antagonists also play an important role in early pregnancy monitoring.
Antagonists can timely adjust the hormone treatment program by monitoring the level of luteinizing hormone and other hormones to maintain the stability of luteal function and endometrium. In addition, antagonists can also improve embryo implantation and pregnancy success rate by monitoring hemodynamics and placental function, assessing pregnancy risk, and taking corresponding preventive and therapeutic measures.
Summary
The combination of IVF protocol antagonists and other adjuvant treatments has played a positive role in improving the success rate of IVF and pregnancy. Combined with ovulation induction therapy, it can improve follicular responsiveness and the development of polycystic follicles. In ovarian adjuvant therapy, the combination with other adjuvant therapies can increase the number and quality of follicles. The application of antagonists in the pretreatment of embryo transfer can select the best embryo and improve the success rate of implantation and pregnancy. In early pregnancy monitoring, the use of antagonists can detect and deal with pregnancy complications as soon as possible, so as to ensure the safety of mothers and infants. Therefore, the combination of IVF protocol antagonists and other adjuvant therapies is an effective treatment strategy.
